About: GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.65 (+0.30%)
GRI NASDAQ GRI Bio Inc.
GRI Bio Inc. share price
Atividade de preço de GRI
Último preço
$ 1,650
Variação (24h)
0,02 USD (1,23%)
Volume
12.51K
Volume (média 4 sem.)
-
Abertura
$ 1,60
Variação do dia
$ 1,60 - $ 1,65
Fechamento anterior
$ 1,63
Último negócio
29 Oct, 2:54 pm GMT+0
Atrasado
29 Oct, 2:54 pm GMT+0
GRI price performance
Atrasado
29 Oct, 2:54 pm GMT+0
quote.marketSignals